LEBANON, N.H.--(BUSINESS WIRE)--Adimab, LLC, a leader in the discovery of fully human antibodies, today announced that its partner, Merrimack Pharmaceuticals, Inc. of Cambridge, MA, has initiated the first human clinical trial of MM-151, an oligoclonal therapeutic consisting of a mixture of three fully human monoclonal antibodies designed to bind to non-overlapping epitopes of the epidermal growth factor receptor (EGFR). The three lead antibodies and a number of backups were discovered by Adimab and licensed exclusively to Merrimack.
